Ziten Tablet contains Teneligliptin 20mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme, Teneligliptin enhances the levels of incretin hormones, which increase insulin secretion in a glucose-dependent manner and decrease glucagon secretion, thereby improving glycemic control. Ziten is prescribed as an adjunct to diet and exercise to improve glycemic parameters in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The 20mg dosage offers effective blood glucose reduction with a favorable safety profile, exhibiting minimal risk of hypoglycemia when used appropriately. Common adverse effects may include nasopharyngitis, headache, and gastrointestinal disturbances, though these are generally mild and transient. Caution is advised in patients with renal or hepatic impairment, and dose adjustments may be necessary based on clinical judgment. Regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic response. Ziten Tablet should be used under medical supervision, with attention to lifestyle modifications including diet and physical activity to optimize diabetes management outcomes.